coteauBeta Get App
MODD

MODD

Modular Medical, Inc.
$1.95
-5.80% Oct 20 close
Healthcare Compare
-90%-63%-36%-9%+17%Oct 2025Oct 2026Apr 2026
MODDSPY
1W
-8.9%
1M
-11.4%
3M
-30.1%
6M
-61.0%
YTD
-82.1%
1Y
-89.3%

Live chart

Loading live chart…

What they do

Healthcare · Medical Devices

For information only · Important disclosures

Grades vs sector

No sector grades for MODD yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Our models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
Outside this model's universe or screens
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
Coteau Long Book
Not in the current book

News

More news
Modular Medical Launches Digital Learning Tools to Support Adoption of Pivot Insulin Delivery System
ACCESS Newswire · Oct 15
Modular Medical to Present at the Webull Emerging & Innovative Companies Webinar on October 14th
ACCESS Newswire · Oct 07
iAccess Alpha Virtual Best Ideas Fall Investment Conference Begins Today with Updated Presentation Schedule
ACCESS Newswire · Sep 15
iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
ACCESS Newswire · Sep 08
Modular Medical to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 on September 15-16, 2026
ACCESS Newswire · Sep 08

Key stats

Market value$18.5M
P/E (next 12 months, estimated)-3.8
52-week range$1.72 – $18.66
Dividend yieldNo dividend
Valuation and fundamentals

Valuation & fundamentals

Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score -2 (DCF counts double).
▼Piotroski F-score2/9
▼Altman Z-13.2 (distress)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2018-12-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.29 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $-0.51 vs trailing $-9.95. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
–
Operating margin
–
FCF margin
–
Net margin
–
Return on equity
-260.4%
Return on invested capital
-315.1%
Net debt / EBITDA
–
Current ratio
3.3×
Interest cover
-9.9×
Cash conversion (OCF/NI)
–
Piotroski F-score 2/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✗ Asset turnover improved

Altman Z-score -13.2 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

No analyst targets available.

Annual history

FYRevenueNet incomeFree cash flow
2018$0––
2017$0––
2017$0––
2016$0––
2015$0––
2014$0––

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

Earnings

Next report: –
23-0623-0823-1124-0224-0624-0824-1125-02-11.700.00
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2025-02-13-3.60-3.90-8.3%
2024-11-14-3.30-4.20-27.3%
2024-08-13-5.55-3.60+35.1%
2024-06-21-6.00-4.20+30.0%
2024-02-13-5.25-6.90-31.4%
2023-11-13-6.45-5.70+11.6%
2023-08-14-11.70-6.60+43.6%
2023-06-26-10.20-9.90+2.9%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–
Analyst actions
Benchmark
2024-03-21 · reit
Speculative Buy → Speculative Buy
PT $5
Oppenheimer
2023-09-19 · reit
Outperform → Outperform
PT $4
Benchmark
2023-06-30 · reit
Speculative Buy → Speculative Buy
PT $5
Oppenheimer
2023-05-19 · main
→ Outperform
PT $4
Benchmark
2023-01-30 · main
→ Speculative Buy
PT $5
Lake Street
2022-04-08 · init
→ Buy
PT $11

Stats refreshed 2026-10-21 01:29:24 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

Beta 0.9 · Oct 21, 2026